Floatz logo

Galcanezumab

Migraine With Aura

Austrian Migraine Registry Collaborationmonoclonal_antibodyActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
81/ 100

Competitive context

21 Active assets in the Migraine With Aura cohort.

Asset / SponsorPhaseRating
Topamax
Tongji Hospital
Phase 4BBB
Dihydroergotamine mesylate
Satsuma Pharmaceuticals, Inc.
Phase 3BB
PROPRANOLOL
Norwegian University of Science and Technology
Phase 3BB
Rimegepant
University of South Florida
Phase 4BB
ALMOTRIPTAN
Messoud Ashina, MD
Phase 4BB

View all 49 →

Same molecule, other indications

Galcanezumab is also rated in:

migraine disorderDormant
BBB
Indicative ·
78 / 100
View asset →
glossopharyngeal neuralgiaDormant
BB
Indicative ·
69 / 100
View asset →
migraine disorderDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →